RAPIBLOC

This brand name is authorized in Austria, Finland, France, Croatia, Netherlands, Romania

Active ingredients

The drug RAPIBLOC contains one active pharmaceutical ingredient (API):

1 Landiolol UNII G8HQ634Y17 - LANDIOLOL HYDROCHLORIDE

Landiolol is a highly selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines adrenaline and noradrenaline on the heart, where beta-1-receptors are predominantly located. Landiolol, as other beta-blockers, is thought to reduce the sympathetic drive, resulting in reduction in heart rate, decrease in spontaneous firing of ectopic pacemakers, slowing the conduction and increase the refractory period of the AV node. Read about Landiolol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RAPIBLOC Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C07AB	Beta blocking agents, selective	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents
Discover more medicines within C07AB
C07AB14		C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective
Discover more medicines within C07AB14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 060885
Country: FR	Base de données publique des médicaments	Identifier(s): 62521323, 67004301
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-922016446
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 161497
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66025001, W66026001